JACK-MA/ALIBABA-FOUND
26.3.2020 04:45:09 CET | Business Wire | Press release
Over 440 medical institutions from 104 countries and regions have applied to learn and share experiences in battling COVID-19 through the International Medical Expert Communication Platform . The Handbook of COVID-19 Prevention and Treatment is now available in seven languages with more to come.
The platform, a centerpiece of the Global MediXchange for Combating COVID-19 (GMCC) program, was jointly established by the Jack Ma Foundation and Alibaba Foundation. It is designed for medical experts around the world to communicate seamlessly with each other to share their invaluable experience of fighting coronavirus disease 2019 (COVID-19) and to ask and answer each other’s questions. To date, the most applications have come in thus far from medical institutions in the U.S, Turkey, the U.K., Pakistan, Spain and Germany.
Medical staff need to apply and be approved to join the platform. Once they’re accepted, they’re free to participate in individual or group discussions and sessions.
“Knowledge is power! We launched an online platform for doctors and nurses around the world to exchange ideas, lessons and know-how to fight the virus. We welcome all hospitals to join Chinese hospitals on this open platform https://covid-19.alibabacloud.com . One world, one fight!" Jack Ma wrote in a tweet Wednesday.
Tapping Alibaba Group’s DingTalk messaging and communications functions, the digital platform provides free audio and video conference functionality, along with live broadcast functions for more-complex scenarios. Medical workers from different countries can choose to communicate with their fellow doctors individually, or they can participate in live-sharing group sessions to interact with multiple participants, using real-time artificial intelligence translation to overcome communication barriers. The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), for example, has been using the platform to share their valuable experience with 92 medical institutions from 44 countries and regions.
A playback function allows further sharing or posting on official websites for consumption anytime – and for those who can’t join the live broadcasts due to the time difference or if they are occupied by their duties.
To date, the International Medical Expert Communication Platform has attracted numerous Chinese medical institutions, including Zhongnan Hospital of Wuhan University (Wuhan Leishenshan Hospital), The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), and others.
Through video conferencing and AI translation from and into 11 languages (Arabic, Chinese, English, French, Indonesian, Japanese, Russian, Spanish, Thai, Turkish, and Vietnamese), the platform aims to build a virtual community.
DingTalk, which powers this platform, has also been tabbed by UNESCO as facilitating distance learning during the coronavirus outbreak.
Also as part of the GMCC programme, the Handbook of COVID-19 Prevention and Treatment , authored by The First Affiliated Hospital, Zhejiang University School of Medicine and compiled according to clinical experience, is now available at no cost in Chinese, English, French, Italian, Japanese, Turkish and Spanish. This handbook provides comprehensive guidelines and best practices by China's top experts for coping with COVID-19. More languages will be added soon, as the GMCC programme continues to launch more anti-epidemic resources and provide more practical suggestions and references for medical staff worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200325005799/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom